#ACR21 Abs#0825 Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ) ⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX ⭐️ Radiographic progression low in all ▶️ Short study w very aggressive 1st line combo Rx https://t.co/TJPZkqmN8z @Rheumnow

• https://bit.ly/3bO6fSP

#ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs ⭐️More pts stay on UPA vs ADA (47 vs 36%) ⭐️Adverse drug events similar between groups. UPA has ⬆️ zoster, lymphopenia, hepatic and CPK elevations https://t.co/eLCytSX7Gz @Rheumnow https://t.co/i8NjSgImVq

• https://bit.ly/3GVdSFD

Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates: 🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️ 🔷High SEC retention rates irrespective of gender @RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo

Gender differences in secukinumab treatment of AS? ⭐️improved disease activity, global function, depression in men and women ⭐️women ⬆️disease burden ⭐️high retention rates irrespective of gender Abs#909 #ACR21 @RheumNow https://t.co/L6mCxuSMo1 https://t.co/pR3OBoXqaT

• How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Pa…

Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX

Dr. R Thomas: current studies on prevention of RA: 👉oral DMARDS (MTX, HCQ) 👉biologics (RTX, abatacept) 👉 studies regulating T cells to restore tolerance 👉biomarkers of tolerant state & look at people who don't develop RA 👉 imaging as window of subclin dz. #ACR21 @rheumnow https://t.co/5bsu5459az

#ACR21 Abs#0818: Starting biologics in moderate vs severe RA activity: ▶️ Moderate disease activity: more likely to reach LDA, remission ▶️ Severe disease: greater overall improvements, but less likely to reach remission https://t.co/9jBtN9wUGF @Rheumnow

• https://bit.ly/31Ec4AB

Tocilizumab biosimilar study. Pharmacokinetic and pharmacodynamic bioequivalence. Delighted to see this, we really need a toc biosimilar after the negative impact of supply shortages of Actemra/Roactemra this year on patients. Abstr#0823 #ACR21 @RheumNow https://t.co/MMVCwaar3r